Clearside Biomedical, Inc. Company profile
About Clearside Biomedical Inc
Clearside Biomedical, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Its proprietary suprachoroidal space (SCS) microinjector targeting SCS offers access to the macula, retina and choroid where sight-threatening disease often occurs. The SCS injection platform is an inherently flexible, in-office, non-surgical procedure intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations. The Company’s suprachoroidal injection platform is a patented approach for delivering pharmacotherapy to the back of the eye through SCS. The Company’s lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Clearside Biomedical Inc revenues increased from $7.9M to $29.6M. Net income totaled $376K vs. loss of $18.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Other expense decrease from $275K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.39 to $0.01.
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)